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Similar risk of exercise-related hypoglycaemia for insulin
degludec to that for insulin glargine in patients with type 1
diabetes: a randomized cross-over trial
We compared changes in blood glucose (BG) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes (T1D) treated with
insulin degludec (IDeg) or insulin glargine (IGlar) in a randomized, open-label, two-period, crossover trial. After individual titration and a steady-state
period, patients performed 30min of moderate-intensity cycle ergometer exercise (65% peak rate of oxygen uptake). BG, counter-regulatory hormones
and hypoglycaemic episodes were measured frequently during and for 24 h after exercise. BG changes during exercise were similar with IDeg and IGlar
[estimated treatment difference (ETD) for maximum BG decrease: 0.14mmol/l; 95% confidence interval (CI) −0.15, 0.42; p= 0.34], as was mean BG (ETD
−0.16mmol/l; 95% CI −0.36, 0.05; p= 0.13). No hypoglycaemic episodes occurred during exercise. Post-exercise mean BG, counter-regulatory hormone
response and number of hypoglycaemic episodes in 24 h after starting exercise were similar with IDeg (18 events in 13 patients) and IGlar (23 events in 15
patients). This clinical trial showed that, in patients with T1D treated with a basal-bolus regimen, the risk of hypoglycaemia induced by moderate-intensity
exercise was low with IDeg and similar to that with IGlar.
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Date submitted 19 June 2015; date of first decision 6 July 2015; date of final acceptance 5 October 2015
Introduction
Physical exercise is beneficial for patients with type 1 diabetes
(T1D), although associated with an increased risk of hypo-
glycaemia [1,2]. Individuals with T1D lack the physiological
adjustments of healthy individuals to maintain euglycaemia
during physical activity [3,4], and may avoid exercise [5].
Published research and practical guidelines recommend indi-
vidual adjustments to insulin dose and carbohydrate intake
[6–8]; however, variation in pharmacodynamic profiles and
duration of action between different basal insulins may alter
their contribution to hypoglycaemia risk.The aimof the present
study was to compare changes in blood glucose (BG) con-
centration and hypoglycaemia risk during and after exercise
in patients with T1D treated with insulin degludec (IDeg) or
insulin glargine (IGlar).
Methods
This single-centre, randomized, open-label, two-period,
multiple-dose, crossover trial complied with the Declaration
of Helsinki [9] and Good Clinical Practice Guidelines [10],
and was approved by the local health authority and ethics
committee.
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This is an open access article under the terms of the Creative Commons Attribution-
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Healthy adults (aged 18–45 years, inclusive) with T1D eligi-
ble for the study had a body mass index (BMI) 18–27 kg/m2,
glycated haemoglobin (HbA1c) level ≤9.5% (80mmol/mol)
and peak rate of oxygen uptake (VO2peak) >35 and <60ml
O2/kg/min, and were performing regular physical cardiores-
piratory activity (≥500 metabolic equivalent of task min per
week [11]) during the last 3months before screening. Exclusion
criteria included cancer, cardiac diseases, supine blood pres-
sure outside the range 90–140mmHg for systolic blood pres-
sure or 50–90mmHg for diastolic blood pressure, recurrent
severe hypoglycaemia or hypoglycaemic unawareness, smoking
and confirmedhyperglycaemia [BG≥17mmol/l (∼306mg/dl)]
during the run-in/steady-state periods. Written informed con-
sent was obtained from all patients. The trial was registered at
ClinicalTrials.gov (NCT01704417).
Patientswere randomized to one of two treatment sequences:
IDeg (Tresiba®, 100 units/ml in 3-ml prefilled investigational
pens, PDS290;NovoNordisk, Bagsværd,Denmark) followed by
IGlar (Lantus®, 100 units/ml in 3-ml SoloStar®; Sanofi, Paris,
France) or IGlar followed by IDeg. The two treatments were
separated by a 7- to 21-day washout). Insulin aspart (IAsp)
(NovoRapid®, 100 units/ml in 3-ml FlexPen®; Novo Nordisk,
Bagsværd, Denmark) was used as bolus insulin.
Treatment periods included a 14- to 28-day titration run-in
on each basal insulin, to reach stable glycaemic control and a
prebreakfast self-measured plasma glucose (SMPG) value of
4–6mmol/l (∼72–108mg/dl). A 6-day steady-state period
followed, during which individual doses were kept constant,
standard meals were served and usual physical activity main-
tained to obtain a reproducible BG profile from day to day,
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Figure 1. Blood glucose concentration (A) during 30min exercise and (B) for up to 22.5 h after start of exercise. Blood samples were taken frequently
(every 5min during exercise and every 10min for 2.5 h after exercise) from time 0 to 3 h, while blood sampling time points in the remaining post-exercise
period are marked by symbols and vertical bars. IDeg, insulin degludec; IGlar, insulin glargine; vertical bars are standard error of the mean.
ensuring BG was controlled before exercise [pre-exercise BG
≥5mmol/l (∼90mg/dl) and ≤10mmol/l (∼180mg/dl); max-
imum difference of 2mmol/l (∼36mg/dl) between the two
exercise bouts].
On day 5 of the steady-state period, patients’ individ-
ual lunchtime IAsp doses (12:00 hours) and carbohydrate
were reduced by ∼60% (median 40 g carbohydrate, both
treatments) to achieve consistent pre-exercise BG levels,
avoiding high BG levels >10mmol/l (∼180mg/dl). Three
hours after lunch (15:00 hours) patients performed a 30-min
ergometer bicycle exercise bout at 65% VO2peak. Gas exchange
and heart rate were measured and %VO2peak and carbohy-
drate oxidation rates during exercise were calculated [12].
Blood was drawn via venous cannula every 5min during
exercise and at various time points for 22.5 h for laboratory
measurement of BG, counter-regulatory hormones and
𝛽-hydroxybutyrate. Hypoglycaemic episodes [plasma glucose
<3.1mmol/l (∼56mg/dl) or episodes requiring assistance of
another person (nocturnal between 00:01 and 05:59 hours,
inclusive)] were recorded for 24 h after start of exercise. Indi-
vidualized corrective carbohydrate doses, adjusted at 10-min
intervals, were given as necessary.
A clinically relevant treatment difference between pre-
exercise BG concentration and minimum BG concentra-
tion during exercise of 0.65mmol/l (∼11.7mg/dl) could be
detected (80% power) with a sample of 36 patients (assum-
ing standard deviation of 1.35). BG concentration endpoints
were analysed in a linear mixed model (BG concentration
before exercise as covariate, treatment and period as fixed
factors, and patient as a random effect). To account for
unequal variances, the within-patient variation depended
on treatment. Rate of hypoglycaemia was analysed in a
negative binomial regression model with a log-link func-
tion (treatment and period as fixed factors and patient
as a random effect). All other endpoints are summarized
descriptively.
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Table 1. Hypoglycaemic episodes [plasma glucose ≤3.1mmol/l (∼56mg/dl) or requiring assistance] with insulin degludec (IDeg) and insulin glargine
(IGlar) during the 24 h after start of exercise.
IDeg IGlar
Hypoglycaemic episodes Episodes Patients (%) Episodes Patients (%)
Hypoglycaemic episodes 18 13 (33.3) 23 15 (37.5)
Nocturnal hypoglycaemic episodes 10 10 (25.6) 10 9 (22.5)
IDeg, insulin degludec; IGlar, insulin glargine.
IDeg, n= 39; IGlar, n= 40.
Results
Of 72 patients screened, 41 were eligible and 40 randomized
(one withdrew). Thirty-nine patients completed the trial, as
one was excluded during the first run-in (BG ≥17mmol/l:
IGlar group). The 35 men and 5 women enrolled had a
mean± standard deviation (s.d.) age of 33.9± 7.7 years, BMI of
23.9± 1.9 kg/m2, VO2peak of 39.4± 3.7ml O2/kg/min, HbA1c
of 7.7± 0.8% (61± 9mmol/mol) and diabetes duration of
16.7± 8.2 years.
The prerequisite that certain parameters were similar
between the two treatments was fulfilled: basal and bolus
insulin doses (Table S1), glycaemic control during steady-state
period (Figure S1), BG concentration immediately before
exercise (Figure 1A), mean relative intensity during the
exercise [VO2peak IDeg: 64.6± 4.1; IGlar: 65.5± 3.8%; (Table
S2)] and pre- and post-exercise heart rate [∼64 and ∼158 bpm,
respectively, with IDeg and IGlar (Figure S2)].
During exercise, endpoints were similar with IDeg and
IGlar, including decrease in BG concentration (Figure 1A),
estimated maximum BG decrease [estimated treatment differ-
ence (ETD): 0.14mmol/l; 95% confidence interval (CI) −0.15,
0.42 (∼2.5mg/dl; 95% CI −2.7, 7.57); p= 0.34], estimated
mean BG concentration [IDeg: 7.28mmol/l (∼131mg/dl);
IGlar: 7.43mmol/l (∼134mg/dl); ETD: −0.16mmol/l; 95%
CI −0.36, 0.05 (∼ −2.9mg/dl; 95% CI −6.5, 0.9); p= 0.13],
respiratory equivalent ratio (>1 for both groups) and carbohy-
drate oxidation [IDeg 2.9± 0.6 and IGlar 2.8± 0.6 g/min
(Table S2)]. There were no hypoglycaemic episodes
nor requirement for carbohydrate administration during
exercise.
The BG concentration for 22.5 h after start of exercise
is shown in Figure 1B. Estimated mean BG concentra-
tion [IDeg: 7.12mmol/l (∼128mg/dl); IGlar: 7.61mmol/l
(∼137mg/dl); ETD: −0.50mmol/l; 95% CI −1.14, 0.15 (∼
−9mg/dl; 95% CI −20.5, 2.7); p= 0.13] and estimated min-
imum BG concentration [IDeg: 6.05mmol/l (∼109mg/dl);
IGlar: 6.39mmol/l (∼115mg/dl); ETD: −0.34mmol/l; 95%
CI −0.88, 0.20 (∼6.1mg/dl; 95% CI −15.9, 3.6); p= 0.21]
for the 2.5 h immediately after exercise were similar between
groups. Concentration of counter-regulatory hormones and
𝛽-hydroxybutyrate showed similar exercise-related changes
for IDeg and IGlar (Figure S3). The number of hypoglycaemic
episodes [estimated rate ratio (ERR) 0.76 (95% CI 0.40, 1.45);
p= 0.39], nocturnal hypoglycaemic episodes [ERR 1.00 (95%
CI 0.40, 2.47); p= 1.00 (Table 1)] and carbohydrate administra-
tions (IDeg: 32 in 14 patients; IGlar: 33 in 12 patients) for 24 h
after start of exercise were similar with IDeg and IGlar.The total
mean± s.d. bolus insulin dose for 24 h after start of exercise
was similar (IDeg 0.29± 0.13 and IGlar 0.33± 0.15 units/kg).
One serious adverse event (hypoglycaemic seizure) occurred
5 days after the IGlar period as a result of a medication error
(IGlar/lispro mix-up). No other relevant safety issues were
raised.
Discussion
The results of the present study show that, despite differ-
ent pharmacodynamic profiles and duration of action, BG
concentrations during and after exercise were similar with
IDeg and IGlar. No hypoglycaemic episodes occurred dur-
ing exercise. The number of hypoglycaemic episodes for 24 h
after start of exercise was low and similar between IDeg and
IGlar, concurring with a recent meta-analysis of self-reported
exercise-related hypoglycaemia with these insulins [13].
In the present study, moderate-intensity cycling increased
tissue fuel requirements above those required when at rest
and represented a useful model for exploring the impact of
basal insulin choice concomitant with the synergistic effect
of muscular contraction on carbohydrate metabolism. We
observed a similarly high rate of carbohydrate oxidation
(IDeg 2.9 g/min and IGlar 2.8 g/min) in exercising patients
(Table S2). Furthermore, sub-maximum cycling caused a
significant counter-regulatory hormone response (Figure S3),
which helped to minimize BG changes from rest during the
exercise period. The equivalent counter-regulatory hormone
response enabled the impact of different basal insulins to be
explored. We found no differences in BG responses despite
markedly different pharmacodynamic profiles of IDeg and
IGlar (Figure 1).
The main strength of the present study was the controlled
setting to achieve similar and reasonable pre-exercise BG
concentrations that were kept within recommended limits [14]
with both treatments. Morning dosing ensured the highest
possible insulin concentration in the circulation at the time of
exercise, particularly for IGlar, with its half-life being half that
of IDeg [15].
The tightly controlled setting limits the applicability of the
study to a real-life situation where patients may not adjust
carbohydrate intake before exercise. This, in conjunction with
a reduced bolus dose, can lead to high pre-exercise BG [1]. In
addition, the experimental design did not include any reduction
in post-exercise bolus dose as this would have complicated data
interpretation, although this has been shown to preserve eug-
lycaemia and prevent hypoglycaemia [8]. Finally, in the present
study, we investigated only one form of exercise and further
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studies might usefully investigate others such as high-intensity
exercise or resistance training.
In summary, this study showed that the risk of hypogly-
caemia in patients with T1D induced by moderate intensity
exercise was low with IDeg and similar compared with IGlar.
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